| Pair Name | (20S)-Protopanaxatriol, EGFR-TKI | ||
| Phytochemical Name | (20S)-Protopanaxatriol (PubChem CID: 11468733 ) | ||
| Anticancer drug Name | EGFR-TKI (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | (20S)-Protopanaxatriol, EGFR-TKI | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Lipid accumulation | |||
| Gene Regulation | Down-regulation | Phosphorylation | EGFR | hsa1956 |
| Down-regulation | Expression | SCD | hsa6319 | |
| In Vitro Model | HCC827 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_2063 |
| PC-9 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_B260 | |
| NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
| HCC827-GR-high1 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_S703 | |
| In Vivo Model | Approximately 1×10⁷ H1975-luc cells were subcutaneously injected into the right hind limbs of mice. | |||
| Result | Our findings uncover a link between lipid metabolic reprogramming and EGFR-TKI resistance, confirmed that combination target both EGFR and abnormal lipid metabolism maybe a promising therapy for EGFR-TKI resistance and highlighting the possibility of monitoring lipid accumulation in tumors for predicting drug resistance. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. doi: 10.1186/s13046-019-1120-4. | Click |
